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Hematopoietic stem cell transplant (HSCT) recipients are at signiﬁcant risk for BK virus (BKV) reactivation,
hemorrhagic cystitis (HC), and renal dysfunction. We prospectively monitored 98 patients who had received
HSCT byserial BKVPCR in the urine throughday (D)þ100 toanalyze the relationshipbetweenBKviruria andHC,
serum creatinine (Cr), and creatinine clearance (CrCl) through D þ180 or death. Patients, median age 52 years
(range, 20 to 73), received T celledepleted (50%) or cord blood allografts (21%). Median pre-HSCT BKV IgG titers
were 1:10,240. Incremental increase in BKV IgG titers correlatedwith developing BK viruria 107 copies/mL. By
D þ100, 53 (54%) patients had BK viruria. BKV load in the urine increased at engraftment and persisted
throughout D þ100. HC developed in 10 patients (10%); 7 of 10 with BK viruria. In competing risk analyses, BK
viruria  107 copies/mL, older age, cytomegalovirus reactivation, and foscarnet use were risk factors for HC. Cr
and CrCl at 2, 3, and 6 months after HSCT were similar between patients with and without BK viruria.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION urine preceded HC, yet values of BK viral load varied widely
BK virus (BKV) is acquired in childhood and establishes
latency in the urothelium. Approximately 90% of adults have
antibodies against BKV [1]. Transient, asymptomatic BKV
shedding in the urine (viruria) may occur in up to 5% of
healthy individuals and up to 60% of immunocompromised
patients [2]. In renal transplant recipients, BKV-associated
nephropathy is a recognized cause of allograft loss [3,4]. An
association between high titers of BKV IgG and BKV ne-
phropathy has also been reported in renal transplant re-
cipients [5]. In hematopoeietic stem cell transplant (HSCT)
recipients, BK viruria is mainly associated with hemorrhagic
cystitis (HC), with a reported incidence ranging from 7% to
40%, depending on HSCT type and HC severity [6-11]. The
prognostic signiﬁcance of the magnitude of viral load in the
urine has not been established in HSCT. In a prospective
study, De Silva et al. did not demonstrate an association be-
tween the level of BK viral load in the urine and HC [6]. In
contrast, Leung et al. showed that a rise in BK viral load in theedgments on page 1209.
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14.04.017and often overlapped between patients with and without HC
[7]. Wong et al., using a laboratory-developed test for BKV
IgG, showed a correlation between high titers of recipient
BKV IgG and rising BK viral load in the urine after HSCT [9].
Recent studies suggest that BK viremia is associated with
renal dysfunction after HSCT [12,13]. Tissue-proven BKV
nephropathy has been rarely reported in HSCT [12-14]. It is
plausible, however, that BKV nephropathy is under-
recognized in HSCT because of a paucity of kidney biopsies
or autopsies for HSCT recipients compared with those for
renal allograft recipients [15].
In the present study, we measured pretransplantation
serum BKV IgG titers and prospectively monitored BK viral
load in the urine by a quantitative PCR in a cohort of 98
adult allogeneic HSCT recipients. Our objectives were the
following: (1) describe the natural history of BKV infection in
urine in our patient population, (2) examine the relationship
between serum BKV IgG titers and BK viruria, and (3) assess
the impact of BK viruria on HC and renal function after HSCT.
METHODS
Patients
The study was reviewed by Memorial Sloan-Kettering Cancer Center’s
(MSKCC) institutional review board and granted a Waiver of Authorization.
The cohort consists of 98 consecutive adult patients who received allogeneicTransplantation.
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2011 through October 2011. Serum creatinine (Cr) values, creatinine clear-
ance (CrCl) values, and data on HC were collected through July 31, 2012 or
death, whichever occurred ﬁrst. Minimum follow-up on survivors was
9 months. Clinical characteristics and laboratory and pharmacy data were
extracted from a computerized database and medical chart review.
Supportive Care
The procedure for T cell depletion (TCD), and grading and managing
graft-versus-host disease has been previously described [16-18]. Recipients
who were cytomegalovirus (CMV) seropositive or had a CMV-seropositive
donor were routinely monitored by CMV PCR at least weekly through day
(D) þ100 and as clinically indicated thereafter. For the present study, CMV
reactivation is deﬁned as  1 PCR of > 500 copies/mL. During the study
period, there was no routine surveillance for other viral pathogens.
Recipients of cord blood (CB) allografts received routine antibacterial
prophylaxis with ciproﬂoxacin starting on D -2 until engraftment or initia-
tion of broad spectrum antibiotics, whichever occurred ﬁrst. Thirty patients
received keratinocyte growth factor (palifermin) 60 mcg/kg intravenously
(i.v.) for 3 consecutive days before conditioning, on D 0 (6 hours after
stem cell infusion), and on D þ1 and þ2. Two patients were enrolled in
double-blinded, placebo controlled, dose-escalation study of the safety,
tolerability, and ability of CMX001 to prevent or control CMV infection
(clinicaltrials.gov, ID:NCT00942305). Fourteen patients received open-label
CMX001. Twelve patients were enrolled in a multicenter, open-label study
of CMX001 for the treatment of serious diseases or conditions caused by
dsDNA viruses (ClinicalTrials.gov, ID:NCT01143181), and 2 patients were
under emergency investigational drug application provisions. The primary
indication for CMX001 was CMV in 13 patients and herpes simplex virus in
1 patient.
Study Design
Recipients’ BKV IgG serum titers were measured within  2 days before
conditioning. Serial urine specimens for quantitation of BKV were collected
at baseline (2 days from conditioning), on D 0  2 days (day of stem cell
infusion), on the day of neutrophil engraftment  2 days, and 1, 2, 4, and
8 weeks after engraftment (3 days). Results of BKV and BKV IgG testing
were not available to the clinicians.
Deﬁnitions
BK viruriawas deﬁned as  1 BKV PCR  500 copies/mL by week 8 after
neutrophil engraftment. High BK viruria was deﬁned as  1 BKV PCR 
1 107 copies/mL [19]. HC was graded as previously described [20] (grade 1,
microscopic hematuria; grade 2, macroscopic hematuria; grade 3, macro-
scopic hematuria with clots; and grade 4, macroscopic hematuria with
impaired renal function secondary to urinary tract obstruction). Grades 3
and 4 HC were deﬁned as severe. Patients with HC grade  2 were treated as
“events” in the analyses. Diagnostic procedures and management of cystitis
were done as per standard care at MSKCC. Urine viral culturewas ordered by
clinicians’ discretion. Symptomatic patients with positive urine bacterial
cultures were excluded from the study.
Laboratory Methods
Serum and urine testing for BKV were performed by Viracor-IBT Labo-
ratories (Lee’s Summit, MO). Serum BKV IgG titers were determined by an
indirect-linked immunosorbent assay (ELISA) to the VP1 viral capsid protein
of BKV. Serumwas serially diluted 4-fold from 1:40 through 1:655,360. The
BKV IgG antibody titer is reported as the specimen dilution that produces
signal greater than the assay background level. Currently, there is no
established clinical cut-off for this assay. Five patients received i.v. immu-
noglobulin G within 30 days before measuring BKV IgG titers.
BKV in the urine was determined by a quantitative polymerase chain
reaction (PCR) assay (linear range of quantitation 500 to > 1  1010 copies/
mL). CMV in whole blood was monitored by a laboratory developed quan-
titative PCR assay using the LightCycler CMV quantitative kit (Roche,
Nutley, NJ). The lower limit of quantitation is  500 copies/mL. Specimens
were batched before testing.
CrCl was estimated using the Cockcroft-Gault equa-tion [21].
Statistical Analyses
Patient and transplantation characteristics were summarized as per-
centage for categorical variables and median (range) for continuous vari-
ables. The Wilcoxon signed rank test was used to compare BK viruria
measured at every pair of neighbor time points, and Bonferroni adjusted
P value was calculated.
We estimated the cumulative incidence rate for BK viruria (BK viral
load  500 copies/mL) and high BK viruria (BK viral load  1.0  107 copies/mL) at Dþ100, treating death and second HSCTas the competing risk. Grey’s
test was used to examine risk factors for HC and high BK viruria after HSCT,
also treating death and second HSCT as the competing risk. Factors with
univariate P value less than .1 were further examined in multivariate anal-
ysis for high BK viruria after HSCT. Because of the small number of events, no
multivariate analysis was performed for HC. Factors observed after HSCT
were treated as time-dependent variables in cause-speciﬁc Cox regression.
The effect of HC on overall survival (OS) was also assessed using time-
dependent cause-speciﬁc Cox regression.
To evaluate the association between BKV status and Cr and CrCl values
recorded at 2, 3, and 6 months, mixed effects models with subject random
effects were used to take into account multiple measurements per patient.
The ﬁxed effects included time, BKV status, and the interaction between BKV
status and time.
Statistical analyses were performed with software package (SAS 9.2; SAS
Institute Inc., Cary, NC). A P value of  .05 was considered statistically
signiﬁcant.
RESULTS
Kinetics of BKV Replication Post-transplantation
Table 1 shows the baseline characteristics of the patients.
Forty-nine (50%) patients received TCD allografts and 21
(21%) patients received double umbilical CB grafts. All (100%)
patients had serum BKV IgG titer> 1:640. The distribution of
BKV IgG titers is shown in Figure 1. At the last follow-up, 35
of 98 patients died. The median follow-up for survivors was
14.2 months (range, 9.4 to 27.6 months) and the median OS
was not reached (95% conﬁdence interval, 15.6 months to not
reached).
During the study period, 53 (54%) patients had BK viruria.
Seven patients had low-level BK viruria (median BK viral load
1900 copies/mL [range, 600 to 6800]). Forty-three (44%)
patients had high BK viruria ( 1  107 copies/mL) after
HSCT. Of those, 21 had BK viruria before stem cell infusion
and 22 developed BK viruria after HSCT.
Figure 2 shows the BK viral loads of patients with BK
viruria from before conditioning to 8 weeks. The median BK
viral load was higher at engraftment (median, 6.8  106
copies/mL [range, < 500 to > 1.0  1010 copies/mL])
compared with day 0 (median of < 500 copies/mL [range,
< 500 to 9  109 copies/mL]) (P < .001). Median BK viral
loads were not different between all other neighboring time
points.
Figure 3 shows the cumulative incidence for BK viruria,
neutrophil engraftment, and HC. Fifty-four percent of pa-
tients (95% conﬁdence interval, 44% to 64%) had BK viruria by
D þ100. The cumulative incidence of BK viruria increased at
the time of neutrophil engraftment and remained stable
after D þ30.
Risk Factors for High BKV Viruria after HSCT
To identify risk factors for high-level BK viruria after
transplantation, patient demographics, transplantation
characteristics, BKV IgG titers, and BK viruria before trans-
plantation were examined in univariate and multivariate
analyses (Table 2). Titers of BKV IgG, high BK viruria before
HSCT, and myeloablative conditioning regimen were impor-
tant in univariate analyses. Titers of BKV IgG (P ¼ .013) and
high BK viruria before HSCT (P < .001) remained signiﬁcant
in multivariate analysis. Peri-transplantation ciproﬂoxacin
was not associated with high BK viruria after HSCT (P¼ .731).
Risk Factors for Hemorrhagic Cystitis
During the study period, 10 patients (10%) developed HC.
HC developed before neutrophil engraftment in 3 patients
and after neutrophil engraftment in 7. Four patients had CMV
Figure 1. Serum BKV IgG titers and BK viruria. X-axis: pretransplantation
serum BKV IgG titers. Y-axis: percentage of patients.
Table 1
Clinical Characteristics of HSCT Recipients
Characteristic N (%)
No. of patients 98
Age, median (range), yr 52.1 (19.6-73)
Gender
Male 60 (61%)
Female 38 (39%)
Underlying disease
Acute leukemia 44 (45%)
Lymphoma/CLL 22 (23%)
Myelodysplastic syndrome/MPD 21 (21%)
Multiple myeloma 9 (9%)
Nonmalignant hematologic disorders 2 (2%)
Stem cell source
Peripheral blood 74 (76%)
Bone marrow 3 (3%)
Cord blood 21 (21%)
Graft type
T celledepleted 49 (50%)
Conventional 49 (50%)
Donor type
Matched related donor 26 (26%)
Matched unrelated donor 32 (33%)
Mismatched unrelated donor 40 (41%)
Type of conditioning
Myeloablative 50 (51%)
Reduced-intensity 38 (39%)
Nonmyeloablative 10 (10%)
Conditioning regimen
Total body irradiation
High dose (>1300 Gy) 17 (17%)
Low dose (400 Gy) 57 (58%)
All chemotherapy 24 (25%)
Acute GVHD
Grade 0-1 64 (65%)
Grade 2-3 32 (33%)
Not evaluable 2 (2%)
Keratinocyte growth factor (palifermin)
Yes 30 (31%)
No 68 (69%)
Ciproﬂoxacin within 14 d of stem cell infusion
Yes 35 (36%)
No 63 (64%)
Recipient serum BKV IgG titers
>1:640 98 (100%)
CMV serology
Rþ/Dþ 28 (28%)
Rþ/D 33 (34%)
R/Dþ 8 (8%)
R/D 29 (30%)
CMV reactivation 37 (38%)
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-
versus-host disease; CMV, cytomegalovirus; Rþ, recipient positive; R,
recipient negative; Dþ, donor positive; D, donor negative; CLL, chronic
lymphocytic leukemia; MPD, myeloproliferative disorders.
Data presented are n (%) unless otherwise indicated.
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enovirus viruria), and 3 had human herpes virus-6 (HHV-6)
viremia. Five patients received i.v. foscarnet at the time of HC
(3 patients for CMV and 2 for HHV-6).
Seven (7% of total) patients had BK viruria at the time of
diagnosis of HC. Three patients received TCD, 3 received CB,
and 1 patient received conventional peripheral stem cell al-
lografts. Two patients had concomitant adenovirus in the
urine. Urine adenovirus was not checked in the remaining 5
patients. In univariate analyses, older age (P ¼ .003), high BK
viruria (P ¼ .001), CMV reactivation (P¼ .028), and treatment
with foscarnet (P < .001) were risk factors for HC. Peri-
transplantation ciproﬂoxacin use was not associated with
hemorrhagic cystitis (P ¼ .094) (Table 3).Recurrence of HC
The clinical characteristics and outcomes of the 7 patients
with HC and BK viruria are shown in supplemental Table S1.
Two patients developed recurrent HC (grade 3 at Dþ271 and
grade 4 at D þ204, respectively).
BK Viruria and Renal Function after HSCT
Cr and CrCl values at 2, 3, and 6months were not different
between patients with and without BK viruria (Figure 4). OS
in patients survived at least 2 months were not different
between BKV-positive patients and BKV-negative patients
(P ¼ .508).
DISCUSSION
HC and renal dysfunction are well-recognized complica-
tions of HSCT. Although several studies report an association
between BKV and HC, a causative link has not been clearly
established [6,7,22,23]. Renal dysfunction is a late compli-
cation of HSCT. Factors implicated in the pathogenesis of
renal dysfunction include toxicity of conditioning regimens,
especially myeloablative regimens containing total body
irradiation, calcineurin inhibitors, older age, and viral in-
fections [12,13,22,24]. Recent studies in conventional HSCT
suggest an association between BKV infection and renal
dysfunction [12]. Recipients of TCD allografts do not receive
calcineurin inhibitors in the absence of graft-versus-host
disease. Thus, the relative contribution of viruses to renal
dysfunction would be more pronounced in this patient
population. Immunity to viral infections, including BKV, is
dependent on the presence of virus-speciﬁc cytotoxic T cells
transferred from the donor. Recipients of TCD or CB allografts
would be expected to be at greater risk for BKV infection and
BKV-related complications because of the absence of BKV-
speciﬁc cells transferred through the allograft.
We prospectively monitored a cohort of 98 HSCT re-
cipients that comprised 50% TCD and 21% cold blood allo-
grafts for BKV in the urine. All HSCT recipients had detectable
BKV IgG before transplantation. Incremental BKV IgG titers
were associated with high BK viruria. Our ﬁndings are in
agreement with published studies in renal allografts and
HSCT using laboratory-developed tests for BKV IgG [5,9]. BK
viruria was observed in approximately 20% of patients before
transplantation and in 50% by neutrophil engraftment. Forty-
seven percent of our cohort had a BK viral load
> 1  107copies/mL. The cumulative incidence of BK viruria
was reached by D þ30, and BK viruria persisted for the
duration of monitoring.
We observed an increase in themagnitude of BK viral load
at the time engraftment. This is a novel observation that
Figure 2. BK viral load among the 53 patients with BK viruria. Dots represent individual patients. Horizontal bars indicate median BK viral load. ANC indicates
absolute neutrophil count; week 0, at ANC (absolute neutrophil count) engraftment; week 1, at 1 week after engraftment; week 2, at 2 weeks after engraftment;
week 4, at 4 weeks after engraftment; week 8, at 8 weeks after engraftment. ANC engraftment is deﬁned as the ﬁrst of day of 3 consecutive measurements of ANC
> 500/mm3.
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reported that HC is preceded by an increase in BK viral load
and suggested that suppression of BK viral load peri-
engraftment may reduce the rate of early HC [25]. In our
cohort, peri-engraftment HC was rare despite the observed
increase in BK viral load, suggesting that additional factors
may be contributing to the pathogenesis of early HC.
Overall, 10 (10%) patients developed HC. Seven patients
had concomitant BK viruria (7% of total study population).
Our rate of HC is consistent with rates reported for conven-
tional bone marrow or stem cell allografts [6]. Higher rates
(up to 26%), however, have been reported in pediatric HSCT
patients [8,11]. During the study period, several changes in
supportive care may have affected rates of HC. Thirty (33%)
patients received peri-transplantation keratinocyte growthFigure 3. Cumulative incidence rates for neutrophil engraftment, BK viruria,
and hemorrhagic cystitis.factor (KGF). In animal models, KGF showed a protective ef-
fect against cyclophosphamide-induced ulcerative hemor-
rhagic cystitis [26]. Successful treatment of HC with KGF has
also been reported [27]. The impact of KGF on HC would be
best addressed in a randomized clinical trial. During the
study, 14 patients received brincidofovir for the treatment of
dsDNA viruses. Although 8 patients received brincidofovir
during the BKV monitoring, they all started after D þ52.
Because the cumulative incidence of BK viruria was reached
by D þ30, it would be unlikely that brincidofovir had an
impact on our observed rates of BK viruria. Only 6 patients
received brincidofovir after the BKV monitoring period,
including 2 patients with BK viruria and HC. CMX001 is
active against BKV and may have affected the risk of devel-
oping HC, but the number of patients who received brinci-
dofovir was low [28]. Ongoing clinical trials of CMX001 in
stem cell transplant recipients will address the role of
CMX001 for prevention of BK viruria and HC. Thirty-ﬁve
patients received ciproﬂoxacin for routine peri-trans-
plantation bacterial prophylaxis or other indications. Cipro-
ﬂoxacin has activity against BKV in vitro and prolonged use
of ciproﬂoxacin has been shown to reduce rates of BK viruria
[25,29]. Leung et al., however, failed to demonstrate a pro-
tective effect of ciproﬂoxacin against HC in HSCT recipients
[25]. In our univariate analyses, peri-transplantation cipro-
ﬂoxacin was not associated with high BK viruria or hemor-
rhagic cystitis. The exposure to ciproﬂoxacin as antibacterial
prophylaxis was brief, so it is unlikely to have had any sig-
niﬁcant impact on the rates of BK viruria and HC.
Older age, high-grade BK viruria before or after HSCT,
CMV infection, and foscarnet use were associated with HC.
CMV is known to have immunomodulatory properties and
may facilitate reactivation of other latent viruses. An asso-
ciation between CMV and BKV reactivation has been sug-
gested in renal allograft recipients but was not conﬁrmed in a
prospective study [3,30]. HC is a recognized side effect of
Table 2
Risk Factors for High BK Viruria (107 copies/mL) after HSCT
Factor Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Age (yr) 1-yr increment 1.00 (.98-1.03) .828
Female ref: male .61 (.32-1.14) .123
Keratinocyte growth factor ref: no .74 (.37-1.46) .383
Titers of BKV IgG 4-fold increment 1.30 (1.00-1.70) .054 1.43 (1.08 to 1.89) .013
Mismatched donor ref: matched* 1.01 (.56-1.83) .963
TCD ref: non-TCD 1.04 (.58-1.87) .903
Cord blood ref: peripheral blood stem cell 1.13 (.61-2.12) .692
Ciproﬂoxacin use ref: no .90 (.49-1.64) .731
Pre-HSCT BKV  1.0  107 ref: < 1.0  107 7.00 (2.80-17.46) <.001 7.26 (2.24 to 23.48) <.001
Myeloablative or reduced-intensity conditioning ref: NMA .41 (.21-.81) .011 .54 (.25 to 1.15) .110
TBI ref: no TBI .83 (.46-1.49) .526
CMV-seropositive recipient ref: seronegative 1.31 (.7-2.46) .405
HSCT indicates hematopoietic stem cell transplantation; KGF, keratinocyte growth factor; TCD, T cell depletion; MA, myeloablative; RIC, reduced intensity; NMA,
nonmyeloablative; TBI, total body irradiation; CMV, cytomegalovirus; ref, reference; CI, conﬁdence interval; BKV, BK virus.
Acute graft versus host disease, forcarnet treatment, and CMX001 treatment were not included because BK viruria occurred before these events.
* Matched donor included matched related donor and matched unrelated donor.
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of our patients received treatment with foscarnet for CMV or
HHV-6 infection. Our sample size precluded multivariate
analyses. Although none of the ﬁrst episodes of HC were
severe (grade 3 or 4), 2 patients with recurrent HC developed
late severe HC. Both patients were severely immunosup-
pressed and had concomitant viral infections, further sup-
porting a multifactorial etiology for late HC.
Studies on the role of polyoma viruses (BKV and John
Cunningham [JC] virus) in renal dysfunction after liver or
kidney transplantation have yielded conﬂicting results.
Kusne et al. reported that BK viruria was not associated with
renal dysfunction in kidney allograft recipients. In contrast,
JC viruria was associated with renal dysfunction in liver
transplant recipients [32]. Recent studies suggest an associ-
ation of BK viremiawith renal dysfunction after conventional
HSCT [12]. We found no difference in Cr or CrCL among pa-
tients with and without BK viruria.
The limitations of our study are inherent to its observa-
tional nature, relatively small sample size, and heterogeneity
of our patient population with regards to underlyingTable 3
Risk Factors for Hemorrhagic Cystitis
Factor
Age (yr) 1-yr increment
Female ref: male
KGF ref: no
Serum BKV IgG titer 4-fold incremen
Mismatched donor ref: matched*
TCD ref: non-TCD
Stem cell source
Cord blood ref: peripheral b
aGVHD grade 2-4y ref: aGVHD grad
Ciproﬂoxacin use ref ¼ no
Pre-HSCT urine BKV  1.0  107 copies/mL ref < 1.0  107
Post-HSCT urine BKV  1.0  107 copies/mLy ref < 1.0  107
MA or RIC ref: NMA
TBI ref: no TBI
CMX001 treatmenty ref: no
Foscarnet treatmenty ref: no
CMV-seropositive recipient ref: seronegativ
CMV reactivationy ref: no
HSCT, hematopoietic stem cell transplantation; KGF, keratinocyte growth factor; T
blative; RIC, reduced-intensity conditioning; NMA, nonmyeloablative; TBI, total bo
BKV, BK virus.
* Matched donor included matched related donor and matched unrelated dono
y The post-transplantation factor was examined as a time-dependent variable indiagnoses, stem cell sources, and conditioning regimens.
Several supportive care modalities were implemented
gradually during the study period that may have affected the
natural history of HC. Also, low rates of HC precluded
multivariate analyses of risk factors. Finally, we monitored
exclusively for BK viruria and not for additional viruses
implicated in HC or renal dysfunction (adenovirus, CMV, or
JC virus) [33].
In summary, (1) rates of BK viruria and HC in TCD and CB
allograft recipients were comparable with rates in conven-
tional allograft recipients, (2) high BKV IgG titers were
associated with “high” BK viruria, (3) BK viral load increased
at neutrophil engraftment and persisted through Dþ100, (4)
although the cumulative incidence for BK viruria was
reached by D þ30, severe BKV-associated HC occurred late
after transplantation, suggesting additional cofactors, and (5)
we could not demonstrate an association between BK viruria
and CrCl in the ﬁrst 6 months after HSCT. Randomized clin-
ical trials are needed to assess the effect of BKV suppression
or keratinocyte growth factor on BK viruria and related
complications in TCD and CB HSCT.Hazard Ratio (95% CI) P Value
1.07 (1.02-1.12) .003
.36 (.08-1.62) .185
.23 (.03-1.88) .170
t 1.06 (.72-1.55) .779
1.04 (.30-3.63) .956
.58 (.17-2.01) .387
lood 2.22 (.56-8.84) .259
e 0-1 3.46 (.63-19.02) .153
.18 (.02-1.34) .094
9.01 (2.61-31.08) .001
9.07 (1.67-49.16) .011
1.51 (.21-10.80) .680
.60 (.16-2.27) .450
2.96 (.35-25.09) .316
20.20 (4.18- 97.66) <.001
e 1.43 (.37-5.52) .600
6.36 (1.22-33.09) .028
CD, T cell depletion; aGVHD, acute graft-versus-host disease; MA, myeloa-
dy irradiation; CMV, cytomegalovirus; ref, reference; CI, conﬁdence interval;
r.
cause-speciﬁc Cox regression.
Figure 4. Comparison of serum creatinine and CrCl between patients with BK and without BK viruria after HSCT at 2, 3, and 6 months. Panel A (left) shows creatinine
comparison between patients with BK and without BK viruria at 2 months, 3 months, and 6 months after HSCT. Panel B (right) shows CrCl comparison between
patients with BK and without BK viruria at 2 months, 3 months, and 6 months after HSCT. The central box represents the values from 25% to 75% and the middle line
represents median. The dot represents outliers. CrCl indicates creatinine clearance; HSCT, hematopoietic stem cell transplantation.
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